Unclassified ยท Medical Literature

[Articles] Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double-blind, non-inferiority trial

Authors
John Burn, Gillian M Borthwick, Faye Elliott, Finlay Macrae, Kai Ren Ong, Alison C Kraus, Nadir Arber, Jukka-Pekka Mecklin, Angel Alonso, Emma R Woodward, D Gareth Evans, Alex Murray, Katie Snape, Ruth E Cleaver, Adam Shaw, Huw J W Thomas, Ajith V Kumar, Dorothy Halliday, Lucy E Side, Rachel E Harrison, Rosemarie Davidson, Ruth Armstrong, Jackie Cook, Rachel Hart, Patrick J Morrison, Julian G Barwell, Alan Donaldson, Zoe Kemp, Jennie Murray, Zosia Miedzybrodzka, Caroline Pottinger, Jonathan Berg, Richard Gallon, D Timothy Bishop, CaPP3 co-investigators
Journal
The Lancet Gastroenterology & Hepatology
Publication date
2026-07-09
Source
rss_lancet_gas
Original record ID
210198
Summary status
error
Analysis status
error
Original last updated
2026-08-10T07:01:51.000Z

Open original source

Abstract

Although non-inferiority could not formally be concluded for either 100 mg or 300 mg of aspirin daily by comparison with 600 mg aspirin daily, there was evidence that the 100 mg dose had similar characteristics to 600 mg in terms of cancer risk but with fewer side-effects and less risk of bleeding.